Navigation Links
Angioslide Announces the European Launch of New 300 mm Long Device Allowing Treatment of Entire Superficial Femoral Artery(SFA) with One Device
Date:9/8/2011

CAESAREA, Israel, September 8, 2011 /PRNewswire/ --

Angioslide Ltd. announces the first procedures with its new 5x300mm PROTEUS device for treating the Superficial Femoral Artery (SFA).  PROTEUS technology combines a Percutaneous Transluminal Angioplasty (PTA) balloon and embolic capture of particles in one device. The new 5x300 mm size joins Angioslide's current dedicated product line solutions for the lower limbs.

Initial treatments using the new PROTEUS device were conducted in leading world centers, Parkkrankenhaus Leipzig and Herzzentrum Bad Krozingen, located in Germany. The PROTEUS 5X300 mm makes it possible to treat lesions up to 300 mm with one device, while providing an immediate solution for embolic capture.

"Angioslide's breakthrough technology, now available also in 300 mm length as well, is a unique solution for lesions with high level of embolic material, including Chronic Total Occlusions (CTO), in stent-restenosis, thrombus containing lesions and post atherectomy PTA," said Prof. Thomas Zeller, Head of the Angiology Department, Heart Center Bad-Krozingen.

Prof.  Dierk Scheinert, Head of the Department of Angiology, Park-Krankenhaus Leipzig, adds, "We have been using the PROTEUS product line as part of our daily practice for a few years, and are working closely with the Angioslide team. I welcome the release of the 5X300 mm.  We can now use one device to treat patients with SFA diseases, which facilitates the procedural flow and makes the intervention cost-effective."

With the increase in life expectancy, diabetes prevalence, and number of high-risk patients, together  with the shift toward an "endovascular-first" approach as a preferred procedure over surgical revascularization, there is a growing need for expanding the current interventional "tool box" to accommodate procedures designed specifically to treat long and diffuse lesions in a quick and effective manner.

"We are committed to introducing new products to the market continuously, addressing the growing range of endovascular solutions," said Lihu Avitov, Angioslide CEO. "With patients' needs in mind, the 5X300 mm device is the first in a series of long balloons, adding to our current offering of 20-100 mm devices. The PROTEUS product family provides additional confidence to clinicians treating their endovascular patients."

The PROTEUS 5X300 mm is currently released for the European market only, and is undergoing an evaluation regulatory process with the FDA.

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic capture. The PROTEUS™ device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic particle capture solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, with regional offices in Europe and the US. For more information visit our website at http://www.angioslide.com

Contact:
Shira Doron
Marketing Director
Mobile: +972-54-9011134
Email: shirad@angioslide.com



'/>"/>
SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):